Directed molecular evolution of DREADDs: A generic approach to creating next-generation RASSLs

Nature Protocols

Volumn 5, Issue 3, 2010, Pages 561-573

  Dong, Shuyun ^a   Rogan, Sarah C ^a   Roth, Bryan L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGNER RECEPTOR EXCLUSIVELY ACTIVATED BY DESIGNER DRUG; DRUG RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL POPULATION; CELL TYPE; CONTROLLED STUDY; DIRECTED MOLECULAR EVOLUTION; EXPERIMENTATION; IN VIVO STUDY; MAMMAL; METHODOLOGY; MOLECULAR LIBRARY; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; YEAST;

DESIGNER DRUGS; DIRECTED MOLECULAR EVOLUTION; DRUG DESIGN; HUMANS; LIGANDS; PHEROMONES; PROTEIN ENGINEERING; RECEPTORS, G-PROTEIN-COUPLED; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 77749320196     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2009.239     Document Type: Article

References (19)

1. Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002).
2. Armbruster, B.N. & Roth, B.L. Mining the receptorome. J. Biol. Chem. 280, 5129-5132 (2005).
3. Roth, B.L., Sheffler, D.J. & Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359 (2004).
4. Keiser, M.J. et al. Predicting new molecular targets for known drugs. Nature 462, 175-181 (2009).
5. Pei, Y., Rogan, S.C., Yan, F. & Roth, B.L. Engineered GPCRs as tools to modulate signal transduction. Physiology 23, 313-321 (2008).
6. Conklin, B.R. et al. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 5, 673-678 (2008).
7. Armbruster, B.N. et al. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. USA 12, 5163-5168 (2007).
8. Guettier, J-M. et al. Profound metabolic effects following selective activation of distinct G protein signaling pathways in pancreatic β cells in vivo. Proc. Natl. Acad. Sci. USA 106, 19197-19202 (2009).
9. Alexander, G.M. et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27-39 (2009).
10. Campbell, J.H., Lengyel, J.A. & Langridge, J. Evolution of a second gene for beta-galactosidase in Escherichia coli. Proc. Natl. Acad. Sci. USA 70, 1841-1845 (1973).
11. Yuan, L., Kurek, I., English, J. & Keenan, R. Laboratory-directed protein evolution. Microbiol. Mol. Biol. Rev. 69, 373-392 (2005).
12. Bloom, J.D. & Arnold, F.H. In the light of directed evolution: pathways of adaptive protein evolution. Proc. Natl. Acad. Sci. USA 106 (Suppl. 1): 9995-10000 (2009).
13. Erlenbach, I. et al. Functional expression of M(1), M(3) and M(5) muscarinic acetylcholine receptors in yeast. J. Neurochem. 77, 1327-1337 (2001).
14. Pausch, M.H. et al. Heterologous G protein-coupled receptors expressed in Saccharomyces cerevisiae: methods for genetic analysis and ligand identification. In Identification and Expression of G Protein-Coupled Receptors (ed. Lynch, K.R.) 196-212 (Wiley-Liss, New York, 1998).
15. Wess, J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 44, 423-450 (2004).
16. Roth, B.L. Drugs and valvular heart disease. N. Engl. J. Med. 356, 6-9 (2007).
17. Bates, B. et al. Characterization of Gpr101 expression and G-protein coupling selectivity. Brain Res. 1087, 1-14 (2006).
18. Huang, X.P. et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-HT2B receptor agonists: implications for drug safety assessment. Mol. Pharmacol. 76, 710-722 (2009).
19. Pei, Y., Dong, S. & Roth, B.L. Generation of designer receptors exclusively activated by designer drugs (DREADDs) by directed molecular evolution. Curr. Protoc. Neurosci. 50, 4.33.1-4.33.25 (2010).